These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31188833)

  • 21. Association Between Body Mass Index and Disability in Children With Charcot-Marie-Tooth Disease.
    Donlevy GA; Garnett SP; Cornett KMD; McKay MJ; Baldwin JN; Shy RR; Yum SW; Estilow T; Moroni I; Foscan M; Pagliano E; Pareyson D; Laura M; Bhandari T; Muntoni F; Reilly MM; Finkel RS; Sowden JE; Eichinger KJ; Herrmann DN; Shy ME; Burns J; Menezes MP
    Neurology; 2021 Oct; 97(17):e1727-e1736. PubMed ID: 34493614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of gait patterns and functional measures between Charcot-Marie-Tooth disease type I and II in children to young adults.
    Pogemiller K; Garibay E; Pierz K; Acsadi G; Õunpuu S
    Gait Posture; 2020 Mar; 77():236-242. PubMed ID: 32062403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease.
    Burns J; Menezes M; Finkel RS; Estilow T; Moroni I; Pagliano E; Laurá M; Muntoni F; Herrmann DN; Eichinger K; Shy R; Pareyson D; Reilly MM; Shy ME
    J Peripher Nerv Syst; 2013 Jun; 18(2):177-80. PubMed ID: 23781965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are novel outcome measures for Charcot-Marie-Tooth disease sensitive to change? The 6-minute walk test and StepWatch™ Activity Monitor in a 12-month longitudinal study.
    Pazzaglia C; Padua L; Pareyson D; Schenone A; Aiello A; Fabrizi GM; Cavallaro T; Santoro L; Manganelli F; Coraci D; Gemignani F; Vitetta F; Quattrone A; Mazzeo A; Russo M; Vita G;
    Neuromuscul Disord; 2019 Apr; 29(4):310-316. PubMed ID: 30926199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuromuscular hip dysplasia in Charcot-Marie-Tooth disease type 1A.
    Bamford NS; White KK; Robinett SA; Otto RK; Gospe SM
    Dev Med Child Neurol; 2009 May; 51(5):408-11. PubMed ID: 19388151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The application of scales and characteristics of disability in the common genotypes of Charcot-Marie-Tooth disease].
    Liu X; Zhang RX; Liu L; Xie YZ; Lin ZQ; Zhao Q; Cao WQ; Zhu XY; Li XB
    Zhonghua Yi Xue Za Zhi; 2021 Jan; 101(2):131-136. PubMed ID: 33455129
    [No Abstract]   [Full Text] [Related]  

  • 27. Randomised controlled trial protocol of foot and ankle exercise for children with Charcot-Marie-Tooth disease.
    Sman AD; Raymond J; Refshauge KM; Menezes MP; Walker T; Ouvrier RA; Burns J
    J Physiother; 2014 Mar; 60(1):55; discussion 55. PubMed ID: 24856942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translation and cross-cultural adaptation of the Charcot-Marie-Tooth disease Pediatric Scale to Brazilian Portuguese and determination of its measurement properties.
    Cruz KLT; Camargos ACR; Cardoso J; de Baptista CRJA; Ramos AD; Mattiello-Sverzut AC; Burns J; Leite HR
    Braz J Phys Ther; 2021; 25(3):303-310. PubMed ID: 32800672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of orthoses on gait in children with Charcot-Marie-Tooth disease.
    Õunpuu S; Garibay E; Acsadi G; Brimacombe M; Pierz K
    Gait Posture; 2021 Mar; 85():198-204. PubMed ID: 33610823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency and circumstances of falls for people with Charcot-Marie-Tooth disease: A cross sectional survey.
    Ramdharry GM; Reilly-O'Donnell L; Grant R; Reilly MM
    Physiother Res Int; 2018 Apr; 23(2):e1702. PubMed ID: 29282812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical outcomes of cavovarus foot deformity in children with Charcot-Marie-Tooth disease.
    Lin T; Gibbons P; Mudge AJ; Cornett KMD; Menezes MP; Burns J
    Neuromuscul Disord; 2019 Jun; 29(6):427-436. PubMed ID: 31122830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of muscle strength, balance and functionality of individuals with type 2 Charcot-Marie-Tooth Disease.
    de França Costa IMP; Nunes PS; de Aquino Neves EL; Lima Santos Barreto LC; Garcez CA; Souza CC; Pereira Oliveira PM; Sales Ferreira LA; Brandão Lima VN; de Souza Araújo AA
    Gait Posture; 2018 May; 62():463-467. PubMed ID: 29674285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploratory study of physical activity in persons with Charcot-Marie-Tooth disease.
    Anens E; Emtner M; Hellström K
    Arch Phys Med Rehabil; 2015 Feb; 96(2):260-8. PubMed ID: 25286435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects.
    Mori L; Prada V; Signori A; Pareyson D; Piscosquito G; Padua L; Pazzaglia C; Fabrizi GM; Smania N; Picelli A; Schenone A;
    Eur J Phys Rehabil Med; 2019 Feb; 55(1):47-55. PubMed ID: 29898585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.
    Burns J; Ouvrier R; Estilow T; Shy R; Laurá M; Pallant JF; Lek M; Muntoni F; Reilly MM; Pareyson D; Acsadi G; Shy ME; Finkel RS
    Ann Neurol; 2012 May; 71(5):642-52. PubMed ID: 22522479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining disability: development and validation of a mobility-Disability Severity Index (mDSI) in Charcot-Marie-tooth disease.
    Ramchandren S; Shy M; Feldman E; Carlos R; Siskind C
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):635-9. PubMed ID: 25157034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of the parent-proxy pediatric Charcot-Marie-Tooth disease quality of life outcome measure.
    Wu TT; Finkel RS; Siskind CE; Feely SME; Burns J; Reilly MM; Muntoni F; Estilow T; Shy ME; Ramchandren S;
    J Peripher Nerv Syst; 2023 Jun; 28(2):237-251. PubMed ID: 36748295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicentre study.
    Padua L; Aprile I; Cavallaro T; Commodari I; La Torre G; Pareyson D; Quattrone A; Rizzuto N; Vita G; Tonali P; Schenone A;
    Neurol Sci; 2006 Dec; 27(6):417-23. PubMed ID: 17205227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electromyographic and biomechanical analysis of step negotiation in Charcot Marie Tooth subjects whose level walk is not impaired.
    Lencioni T; Piscosquito G; Rabuffetti M; Sipio ED; Diverio M; Moroni I; Padua L; Pagliano E; Schenone A; Pareyson D; Ferrarin M
    Gait Posture; 2018 May; 62():497-504. PubMed ID: 29679921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
    Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.